SVP & Chief Technology Officer Sestrick Michael Robert was granted 2,016 shares and covered exercise/tax liability with 1,045 shares, increasing direct ownership by 26% to 4,762 units (SEC Form 4)

$BCPC
Major Chemicals
Industrials
Get the next $BCPC alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sestrick Michael Robert

(Last) (First) (Middle)
C/O BALCHEM CORPORATION
5 PARAGON DRIVE

(Street)
MONTVALE NJ 07645

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BALCHEM CORP [ BCPC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP & Chief Technology Officer
3. Date of Earliest Transaction (Month/Day/Year)
02/12/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/13/2025 A 2,016(1) A $0 5,807 D
Common Stock 02/13/2025 F 1,045(2) D $163.14 4,762 D
Common Stock 848 I 401(k) Plan
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the vesting of performance stock units (includes 33 dividend equivalent shares) for the 2022-2024 performance period.
2. 1,045 of the 2,016 performance stock units that vested on February 13, 2025 were withheld to cover tax requirement due upon vesting.
/s/ Travis Larsen, Attorney in Fact for Michael Robert Sestrick 02/14/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $BCPC alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BCPC

DatePrice TargetRatingAnalyst
3/8/2022$170.00 → $155.00Buy
HC Wainwright & Co.
2/22/2022$175.00Neutral → Buy
Sidoti
1/10/2022$160.00 → $170.00Buy
HC Wainwright & Co.
11/29/2021$175.00Buy → Neutral
Sidoti
8/2/2021$140.00 → $145.00Overweight → Equal-Weight
Stephens & Co.
8/2/2021$145.00 → $160.00Buy
HC Wainwright & Co.
More analyst ratings

$BCPC
Press Releases

Fastest customizable press release news feed in the world

See more
  • Balchem Corporation to Participate in the BNP Paribas Exane 13th Consumer Ingredients Conference on March 11, 2025

    MONTVALE, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will participate in the BNP Paribas Exane 13th Consumer Ingredients Conference on March 11, 2025. Ted Harris, Chairman of the Board, Chief Executive Officer, and President, Martin Bengtsson, Chief Financial Officer, and Allison Baurichter, Senior Director Investor Relations will participate at the conference. About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solu

    $BCPC
    Major Chemicals
    Industrials
  • Balchem Corporation Reports Fourth Quarter and Full Year 2024 Financial Results

    MONTVALE, N.J., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2024 fiscal fourth quarter ended December 31, 2024. For the quarter, the Company reported net sales of $240.0 million, net earnings of $33.6 million, adjusted EBITDA(a) of $62.8 million, and free cash flow(a) of $39.8 million. Ted Harris, Chairman, President, and CEO of Balchem said, "The fourth quarter capped off another very strong year for Balchem. We delivered record fourth quarter net sales and adjusted EBITDA, with top and bottom line year over year growth in each of our three segments." Fourth Quarter 2024 Financial Highlights:

    $BCPC
    Major Chemicals
    Industrials
  • Balchem Corporation Announces Quarterly Conference Call for Fourth Quarter and Full Year 2024 Financial Results on February 21, 2025

    MONTVALE, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Friday, February 21, 2025, at 11:00 AM Eastern Time (ET) to review fourth quarter and full year 2024 results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Fourth quarter and full year results will be published prior to the market opening on Friday, February 21, 2025. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. We invite you to listen to the conference by calling toll-free 1-87

    $BCPC
    Major Chemicals
    Industrials

$BCPC
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$BCPC
SEC Filings

See more

$BCPC
Leadership Updates

Live Leadership Updates

See more
  • AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors

    BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted non-systemic, therapies for gastrointestinal (GI) diseases, today announced the appointment of Terry Coelho to its Board of Directors effective immediately. The appointment increases the size of AzurRx's Board to seven members. Ms. Coelho currently serves as the Executive Vice President and Chief Financial Officer at BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a commercial-stage specialty pharmaceutical company. During her more than 30-year career, Ms. Coelho has held numerous senior level financial an

    $AZRX
    $BCPC
    $BDSI
    Major Pharmaceuticals
    Health Care
    Major Chemicals
    Industrials

$BCPC
Financials

Live finance-specific insights

See more
  • Balchem Corporation Reports Fourth Quarter and Full Year 2024 Financial Results

    MONTVALE, N.J., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2024 fiscal fourth quarter ended December 31, 2024. For the quarter, the Company reported net sales of $240.0 million, net earnings of $33.6 million, adjusted EBITDA(a) of $62.8 million, and free cash flow(a) of $39.8 million. Ted Harris, Chairman, President, and CEO of Balchem said, "The fourth quarter capped off another very strong year for Balchem. We delivered record fourth quarter net sales and adjusted EBITDA, with top and bottom line year over year growth in each of our three segments." Fourth Quarter 2024 Financial Highlights:

    $BCPC
    Major Chemicals
    Industrials
  • Balchem Corporation Announces Quarterly Conference Call for Fourth Quarter and Full Year 2024 Financial Results on February 21, 2025

    MONTVALE, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Friday, February 21, 2025, at 11:00 AM Eastern Time (ET) to review fourth quarter and full year 2024 results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Fourth quarter and full year results will be published prior to the market opening on Friday, February 21, 2025. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. We invite you to listen to the conference by calling toll-free 1-87

    $BCPC
    Major Chemicals
    Industrials
  • Balchem Corporation Announces Dividend

    MONTVALE, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that on December 9, 2024, its Board of Directors declared a dividend on its shares of common stock equal to $0.87 per share on the Company's issued and outstanding Common Stock, to be payable on January 17, 2025 to stockholders of record at the close of business on December 26, 2024. This dividend represents an 10.1% increase over last year's annual dividend. Ted Harris, Balchem's Chairman, President and CEO, said, "Balchem has a long-standing commitment to an annual dividend and we are pleased to announce the continuation of that commitment. This dividend represents the sixteenth consecuti

    $BCPC
    Major Chemicals
    Industrials

$BCPC
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more